Test From (DO NOT USE)

Only request the minimum access level that you require. You must provide more documentation to be approved for higher levels of access.

Provide a title for your study along with a short (<5 characters) abbreviation that you want TIES to use when referring to your study.

For studies that involve FFPE, a local pathologist is required.

If you are planning to request access to FFPE, but you are not planning to use the HSTB through your pathologist, please provide the name of an alternative honest broker.

List information for up to three additional users below.

The TIES Cancer Research Network (TCRN) is a national network of interconnected tissue archives. Partners include Augusta University, Roswell Park Cancer Institute, University of Pennsylvania, and University of Pittsburgh.

The TCRN only provides access to Pathology data and tissue. You will have access to Radiology data only from the University of Pittsburgh.

Due to regulatory requirements, you must follow additional steps when conducting a TCRN study with biomaterials. You will need to complete the TCRN Specimen and Data Request Form. Once it has been determined that materials are available and can be shared, you will need to complete a Uniform Biological Material Transfer Agreement (UBMTA) before ordering tissue or other biomaterials. You must also agree to pay any fees for use of biomaterials. More information on these requirements can be found here [website URL].

The AU TIES node currently captures only Surgical Pathology reports for which cognate FFPE blocks can be tracked. A subset of cases are represented in the AU Biorepository for which flash frozen and serum samples may be available through a separate database query. No TMA blocks are currently available.

For studies that involve FFPE, a local pathologist is required.

Roswell Park Cancer Institute offers access to the following biomaterials from 3 different biobanks: Formalin fixed paraffin embedded tissues, remnant human frozen tissue, DNA and RNA, tissue microarrays from solid tumors. Hematological oncology specimens include components frozen from bone marrow, peripheral blood and cord blood. These include serum, plasma, PBMC, BMMC. Blood products including serum, plasma, buffy coat, RBCs, DNA and whole blood are also available across most disease sites. Use of any specimens will be considered on a case-by-case basis and must first be approved by organ specific Disease Site Research Groups which act as Tissue Utilization Committees.

The Clinical Data Network can provide clinical data other than that which is contained within the pathology report. They will act as Honest Brokers and will interact with all banks to correlate samples with the clinical data needed for the study.

Cost recovery charges will apply for all services rendered.

For studies that involve FFPE, a local pathologist is required.

The Penn Medicine BioBank offers access to the following biomaterials: frozen tissue, tissue in OCT, FFPE, and blood as plasma, serum, whole blood and DNA. Access to these materials will be considered on a case-by-case basis and may require collaboration with a Penn investigator. Fees may apply.

For studies that involve FFPE, a local pathologist is required.

The University of Pittsburgh offers access to the following biomaterials: HSTB contains over 107,410 tissue samples and 506,115 bio-fluid samples including blood, urine, gastrointestinal, genitourinary, breast, and gynecological specimens, among many others. Use of any specimens will be considered on a case-by-case basis and must first be approved by the organ-specific Tissue Utilization Committee. In addition, the HSTB has access to the FFPE case material of patients who have been seen within the UPMC Health System. This material is property of the UPMC Department of Pathology, for which an agreement has been made allowing access for TCRN researchers. All requests will be reviewed by a pathologist and must have approval from the COE prior to release.

For studies that involve FFPE, a local pathologist is required.